York Pharma completes acquisition from Solvay
This article was originally published in Scrip
Executive Summary
York Pharmahas completed its €28.5 million acquisition of the dermatological and wound care products Flammazine and Flammacerium fromSolvay Pharmaceuticals. Solvay will receive €17 million up-front and an additional €11.5 million by the end of the year. Flammazine and Flammacerium, both of which contain silver sulfadiazine, are sold in 21 countries and have annual sales of around £8.5 million.